Axogen has agreed to acquire BioCircuit Technologies for $200 million, aiming to expand its peripheral nerve repair offerings. The deal, announced Thursday, will be funded through a public equity offering expected to raise about $208.7 million. This acquisition marks a significant step for Axogen in broadening its product portfolio and enhancing its market position in the nerve repair sector.
A Strategic Move for Axogen
Axogen said its commercial infrastructure, surgeon relationships, and hospital contracting would help accelerate adoption and expand access to BioCircuit’s NerveTape technology. NerveTape is a sutureless device that connects transected nerves without the need for microsuturing, potentially speeding up nerve repair procedures. This innovation is particularly valuable in reducing surgery time and improving patient outcomes, as it eliminates the complex and time-consuming microsuturing process.
According to the company, surgeons in multiple nerve repair settings have already adopted the technology, with clinical experience confirming its performance and safety profile. The NerveTape platform may also support future product development and expansion into new indications. By integrating NerveTape, Axogen aims to address a broader range of nerve repair challenges, from acute injuries to chronic conditions, further solidifying its leadership in the field.
Investor Concerns Over Financing
While analysts called the acquisition a good fit for Axogen, they noted that the company’s plans to finance the deal with a public stock offering could be a point of contention for investors. Axogen’s stock was down more than 10% to $42.46 Thursday morning, reflecting immediate market skepticism. The dilution effect of issuing new shares often raises concerns about reduced earnings per share and potential undervaluation of existing stock.
Truist Securities analysts wrote to clients that the benefit of NerveTape to clinicians should help Axogen accelerate its expansion in the nerve repair market. However, they acknowledged that the incremental dilution from the equity raise might be viewed negatively by investors. Despite this, the analysts emphasized the long-term strategic value of the acquisition, citing the potential for market share growth and enhanced profitability.
Read Also: FDA’s generative AI strategy faces four key questions
Despite these concerns, the analysts believe the transaction rationale makes sense, given the growth potential from the incoming asset, overall margin accretion, and strategic fit. Axogen expects the deal to add to its revenue growth and adjusted earnings in the first year after closing, positioning the company for sustained success in a rapidly evolving medical technology sector.
Next Steps for the Acquisition
The deal, approved by the boards of both Axogen and BioCircuit, is expected to close in the fourth quarter. It is subject to conditions, including the completion of the spin-out of BioCircuit’s electronics research and development business. This spin-out will allow BioCircuit to focus exclusively on its core nerve repair technologies, ensuring a seamless integration with Axogen’s operations.
Axogen CFO Lindsey Hartley said in a statement, “BioCircuit has developed a highly differentiated technology that complements our existing portfolio and expands our ability to serve surgeons across the continuum of nerve repair.” This acquisition aligns with Axogen’s broader strategy to innovate and lead in the nerve repair market, leveraging cutting-edge technologies to improve patient care.
As the acquisition moves forward, Axogen will likely focus on integrating BioCircuit’s technology into its existing offerings, leveraging its commercial infrastructure to drive adoption and growth in the nerve repair market. By combining BioCircuit’s innovative solutions with Axogen’s established market presence, the company is poised to set new standards in nerve repair technology and patient outcomes.
